Search

Fagron

Chiusa

SettoreSettore sanitario

22.45 -1.1

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

22.2

Massimo

22.8

Metriche Chiave

By Trading Economics

Entrata

46M

Vendite

476M

P/E

Media del settore

19.402

89.037

Rendimento da dividendi

1.53

Margine di Profitto

9.569

Dipendenti

3,989

EBITDA

87M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+20.59% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

1.53%

2.18%

Utili prossimi

19 feb 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

1.7B

Apertura precedente

23.55

Chiusura precedente

22.45

Notizie sul Sentiment di mercato

By Acuity

100%

0%

345 / 360 Classifica in Healthcare

Fagron Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

21 gen 2026, 23:49 UTC

I principali Market Mover

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21 gen 2026, 21:12 UTC

I principali Market Mover

Automaker Stocks Rise After Trump Calls Off European Tariffs

21 gen 2026, 21:00 UTC

Acquisizioni, Fusioni, Takeovers

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21 gen 2026, 20:29 UTC

I principali Market Mover

Chip Makers Gain After Trump Calls Off European Tariffs

21 gen 2026, 20:04 UTC

I principali Market Mover

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21 gen 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21 gen 2026, 23:34 UTC

Discorsi di Mercato

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21 gen 2026, 22:39 UTC

Utili

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21 gen 2026, 21:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

21 gen 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

21 gen 2026, 21:35 UTC

Acquisizioni, Fusioni, Takeovers

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21 gen 2026, 21:19 UTC

Utili

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21 gen 2026, 20:45 UTC

Acquisizioni, Fusioni, Takeovers

Deutsche Borse Group to Acquire Allfunds for $6.19B

21 gen 2026, 20:36 UTC

Discorsi di Mercato

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21 gen 2026, 20:31 UTC

Discorsi di Mercato

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21 gen 2026, 20:27 UTC

Acquisizioni, Fusioni, Takeovers

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21 gen 2026, 20:27 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

21 gen 2026, 20:27 UTC

Discorsi di Mercato

Was It a 'TACO' Event? -- Market Talk

21 gen 2026, 20:26 UTC

Acquisizioni, Fusioni, Takeovers

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21 gen 2026, 20:23 UTC

Acquisizioni, Fusioni, Takeovers

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21 gen 2026, 20:21 UTC

Acquisizioni, Fusioni, Takeovers

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21 gen 2026, 20:19 UTC

Acquisizioni, Fusioni, Takeovers

Deutsche Boerse Group Agrees to Buy Allfunds

21 gen 2026, 20:08 UTC

Utili

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21 gen 2026, 20:03 UTC

Discorsi di Mercato

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21 gen 2026, 19:51 UTC

Discorsi di Mercato

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21 gen 2026, 19:43 UTC

Discorsi di Mercato

U.S. Ethanol Production Expected to Slip -- Market Talk

21 gen 2026, 19:31 UTC

Discorsi di Mercato

Gold Settles at Fresh All-Time High -- Market Talk

21 gen 2026, 19:24 UTC

Utili

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21 gen 2026, 19:10 UTC

Discorsi di Mercato

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21 gen 2026, 18:57 UTC

Discorsi di Mercato

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Fagron Previsione

Obiettivo di Prezzo

By TipRanks

20.59% in crescita

Previsioni per 12 mesi

Media 19.5 EUR  20.59%

Alto 19.5 EUR

Basso 19.5 EUR

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Fagron - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

1

Acquista

0

Mantieni

0

Vendi

Sentiment

By Acuity

345 / 360 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Fagron

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
help-icon Live chat